Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

被引：0
|
作者：
Giles, F
Tallman, M
Garcia-Manero, G
Cortes, J
Thomas, D
Wierda, W
Verstovsek, S
Hamilton, M
Barrett, E
Albitar, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] OSI Pharmaceut Inc, Boulder, CO USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4732
引用
收藏
页码：251B / 251B
页数：1
相关论文
共 50 条
  • [31] Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors
    Beutel, G
    Glen, H
    Schöffski, P
    Chick, J
    Gill, S
    Cassidy, J
    Twelves, C
    CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5487 - 5495
  • [32] Phase I study of liposomal daunorubicin in patients with acute leukemia
    Cortes, J
    O'Brien, S
    Estey, E
    Giles, F
    Keating, M
    Kantarjian, H
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 81 - 87
  • [33] Phase I study of liposomal daunorubicin in patients with acute leukemia
    Jorge Cortes
    Susan O'Brien
    Elihu Estey
    Francis Giles
    Michael Keating
    Hagop Kantarjian
    Investigational New Drugs, 1999, 17 : 81 - 87
  • [34] Clinical phase-I and pharmacokinetic study with liposomal doxorubicin (DL-1) in patients with advanced metastatic cancer.
    Mross, K
    Gierlich, T
    Zigler-Widmer, G
    Häring, B
    März, W
    Sauer, U
    Eibl, H
    Unger, C
    ANNALS OF ONCOLOGY, 2000, 11 : 137 - 137
  • [35] Phase I study of temozolomide and cisplatin in patients with acute leukemia.
    Katragadda, Sreedhar
    Liu, Delong
    Halicka, Dorota
    Kempin, Sanford
    Ahmed, Nasir
    Ahmed, Tauseef
    Seiter, Karen
    BLOOD, 2006, 108 (11) : 215B - 215B
  • [36] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    Twelves, CJ
    Gardner, C
    Flavin, A
    Sludden, J
    Dennis, I
    de Bono, J
    Beale, P
    Vasey, P
    Hutchison, C
    Macham, MA
    Rodriguez, A
    Judson, I
    Bleehen, NM
    BRITISH JOURNAL OF CANCER, 1999, 80 (11) : 1786 - 1791
  • [37] Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
    C J Twelves
    C Gardner
    A Flavin
    J Sludden
    I Dennis
    J de Bono
    P Beale
    P Vasey
    C Hutchison
    M A Macham
    A Rodriguez
    I Judson
    N M Bleehen
    British Journal of Cancer, 1999, 80 : 1786 - 1791
  • [38] Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
    Infante, Jeffrey R.
    Keedy, Vicki L.
    Jones, Suzanne F.
    Zamboni, William C.
    Chan, Emily
    Bendell, Johanna C.
    Lee, Wooin
    Wu, Huali
    Ikeda, Satoshi
    Kodaira, Hiroshi
    Rothenberg, Mace L.
    Burris, Howard A., III
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 699 - 705
  • [39] Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
    Jeffrey R. Infante
    Vicki L. Keedy
    Suzanne F. Jones
    William C. Zamboni
    Emily Chan
    Johanna C. Bendell
    Wooin Lee
    Huali Wu
    Satoshi Ikeda
    Hiroshi Kodaira
    Mace L. Rothenberg
    Howard A. Burris III
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 699 - 705
  • [40] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
12345